Biohaven Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BHVN New York 2830 www.biohaven.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biohaven Ltd.

Biohaven’s epilepsy drug hit with FDA clinical hold - Sep 11th, 2026 5:17 am
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback - Sep 10th, 2026 2:17 pm
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. - Sep 10th, 2026 12:14 pm
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials - Sep 10th, 2026 8:10 am
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - Sep 10th, 2026 7:45 am
FDA places partial hold on Biohaven’s epilepsy drug - Sep 10th, 2026 6:13 am
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says - Sep 8th, 2026 10:29 am
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target - Sep 8th, 2026 4:53 am
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet - Sep 3rd, 2026 5:59 am
Why Biohaven Stock Was Rocking the Market This Week - Aug 28th, 2026 1:32 am
Slate Medicines Starts Migraine Treatment Study - Aug 27th, 2026 3:49 pm
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race - Aug 27th, 2026 8:40 am
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program - Aug 27th, 2026 7:42 am
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Aug 26th, 2026 11:00 am
Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal - Aug 26th, 2026 6:28 am
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal - Aug 26th, 2026 5:17 am
SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim' - Aug 26th, 2026 3:29 am
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy - Aug 26th, 2026 12:01 am
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - Aug 14th, 2026 4:23 pm